Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

60 results about "Deoxycytidine" patented technology

Deoxycytidine is a deoxyribonucleoside, a component of deoxyribonucleic acid. It is similar to the ribonucleoside cytidine, but with one hydroxyl group removed from the 2' position. Deoxycytidine can be phosphorylated by deoxycytidine kinase (DCK).

False positive reduction by translesion polymerase repair

PCT designated stage expiredWO2024249466A1Microbiological testing/measurementCytosine deaminaseBase J
Described herein are methods, compositions, and kits for removing false positive uracils due to the deamination of unmethylated cytosines in assays using engineered cytosine deaminases to deaminate methylated cytosines. The methods, compositions, and kits utilize a dual enzymatic process. After cytidine deaminase treatment, the DNA is first incubated with Uracil DNA Glycosylase (UDG), which generates abasic sites where dC to dU conversions have occurred. The DNA is then incubated with a high-fidelity polymerase supplemented with a deoxycytidyl transferase, such as Rev1, to repair the lesion with the installation of a cytidine.
Owner:ILLUMINA INC

Carbocyclic nucleoside analogue

To provide a novel hydrolytically stable carbocyclic 5-aza-2'-deoxycytidine.SOLUTION: The present invention provides carbocyclic 5-aza-2'-deoxycytidine as shown below, wherein R1 and R2 are each independently H, a free or protected, modified or unmodified phosphate group, or a hydroxyl protecting group; R3 is H, F, CH3, CH2F, CHF2, CF3, OH, or OR6 (R6 is a hydroxyl protecting group); and R4 and R5 are each independently H or the like.SELECTED DRAWING: None
Owner:LUDWIG MAXIMILIANS UNIV MUNCHEN

Combination comprising deoxycytidine derivative and PARP inhibitor for use in method of treating HR-functioning cancer

The present invention relates to a pharmaceutical combination comprising a PARP inhibitor and a compound of formula (I), or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof, for use in a method of treating HR-functioning cancer, the pharmaceutical combination comprising a PARP inhibitor and a compound of formula (I): or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof;
Owner:SIFANG BIOSCIENCE CO LTD

Method for improving bioavailability of nucleoside drug substances

The invention provides a method for improving the bioavailability of a nucleoside drug for treating mitochondrial depletion syndrome. In particular, the methods involve increasing the bioavailability of deoxycytidine and deoxythymidine by administering a therapeutically effective amount of deoxycytidine and deoxythymidine with food.
Owner:YOUSIPI BIOSCIENCES CO LTD

Method for detecting SLE

An object of the present invention is to provide a method capable of detecting whether a subject has systemic lupus erythematosus (preferably nephrotic syndrome) with high accuracy without performing a renal biopsy, a biomarker for carrying out such detection, and the like. The concentration of 3′,4′-didehydro-3′-deoxycytidine in urine collected from a test subject is measured, and this concentration is compared with a reference concentration for control, which allows to detect whether the above-mentioned test subject has systemic lupus erythematosus (preferably lupus nephritis) with high accuracy.
Owner:KEIO UNIV +1

Antisense oligonucleotides (ASOS) for treatment of cardiac and fibrotic disorders

PCT designated stageWO2026175977A2DiseasePhysiology
Provided herein is an antisense oligonucleotide for targeting long non-coding RNA maternally expressed gene 3 (IncRNA Meg3), wherein the oligonucleotide comprises or consists of one of the following sequences in the 5' to 3' direction: (I) C G C dC dG dC dC dA dT dA dT dC dT C C C (SEQ I D NO: 1 ); (ii) C G G dA dC dA dA dA dA dC dT dG dG T T G (SEQ ID NO: 2); (ill) A A G dA dG dT dC dT dC dC dT dC dC dT T A A (SEQ ID NO: 3); (iv) G A T dT dA dG dC dC dC dT dG dT dG dT T C A (SEQ ID NO: 4); (v) C G G dC dA dC dA dA dG dA dG dC dC dA A A G (SEQ ID NO: 5); (vi) T O T dC dC dT dC dC dT dT dA dA dG dC C C C (SEQ ID NO: 6); or (vii) G T C dT dC dC dT dC dC dT dT dA dA dG C C C (SEQ ID NO: 7); wherein dA, dT, dG and dC are deoxyribonucleotides, or wherein dC is 5-methyl-2'-deoxycytidine; and wherein A, T, G and C are modified or unmodified nucleotide building blocks.

Method for preparing 4'-thio-5-aza-2'-deoxycytidine

The present invention relates to a method for preparing 4′-thio-5-aza-2′-deoxycytidine which exhibits DNMT1 inhibitory activity. The production method according to the present invention can enhance reaction efficiency through efficient process development and can stereoselectively prepare 4′-thio-5-aza-2′-deoxycytidine, and thus is economical and appropriate for mass production.
Owner:PINOTBIO INC +1

Application of 2 '-deoxycytidine in preparation of medicine for treating atherosclerosis

The invention discloses an application of 2 '-deoxycytidine or a pharmaceutical salt thereof in preparation of a medicine for preventing or treating atherosclerosis. The invention develops a new application of the 2 '-deoxycytidine, and also provides a new thought for prevention and treatment of atherosclerosis related cardiovascular diseases. Researches find that 2 '-deoxycytidine can significantly inhibit macrophage lipid accumulation and reduce ApoE <- / -> mouse atherosclerotic plaque formation. What's more important is that the inhibition effect of 2 '-deoxycytidine on Dax1 is stronger than that of decitabine.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Method for preparing 4 '-thio-5-aza-2'-deoxycytidine

The present invention relates to a method for preparing 4 '-thio-5-aza-2'-deoxycytidine exhibiting DNMT1 inhibitory activity, and more particularly, to a method for preparing 4 '-thio-5-aza-2'-deoxycytidine exhibiting DNMT1 inhibitory activity, the method for preparing 4 '-thio-5-aza-2'-deoxycytidine according to the present invention can improve reaction efficiency through efficient process development and can stereoselectively prepare 4 '-thio-5-aza-2'-deoxycytidine, thereby being economical and suitable for large-scale production.
Owner:PINON BIOTECHNOLOGY CO LTD +1

Preparation method and application of H-phosphonate solid-phase linker

The invention discloses an H-phosphonate solid-phase connexon, a preparation method thereof and application of the H-phosphonate solid-phase connexon in solid-phase flow synthesis of circular nucleic acid. According to the preparation method, a solid-phase synthesis technology is adopted, exposed amino resin and succinic anhydride are subjected to a condensation reaction to obtain a solid-phase carrier with carboxylic acid, then the solid-phase carrier and 5 '-O-(4, 4'-dimethoxytriphenylmethyl) deoxycytidine are subjected to an amidation reaction under the assistance of a condensing agent and a condensation activating agent, loading of deoxycytidine is achieved, and finally H-phosphonation of hydroxyl is completed. The H-phosphonate solid-phase linker is obtained. The linker disclosed by the invention can realize cyclization closure of a linear precursor by utilizing an efficient reaction between an H-phosphonate group and a terminal hydroxyl group of the linker. The synthesis strategy has the remarkable advantages that the cyclization process can be completed only in 6 hours, and the separation yield reaches up to 73%. The whole process condition is mild, the operation is simple and convenient, the reaction is rapid, and the gram-scale preparation of the cyclic nucleic acid can be efficiently realized.
Owner:ZJU HANGZHOU GLOBAL SCI & TECH INNOVATION CENT

High-activity deoxycytidine monophosphate deaminase mutant and application thereof

The invention discloses a preparation method of a high-activity deoxycytidine monophosphate deaminase mutant, and relates to the technical field of bioengineering, and the preparation method comprises the following steps: 1, synthesizing a deoxycytidine monophosphate deaminase female parent and a mutant gene; 2, screening dominant mutants; 3, purifying deoxycytidine monophosphate deaminase and the mutants; and 4, determining the specific enzyme activity of the enzyme. A plurality of mutation sites are introduced through a site-specific mutagenesis technology to optimize the catalytic performance of the deoxycytidine monophosphate deaminase, and required mutation is introduced into a specific position of the enzyme, so that the accurate regulation and control of the catalytic performance of the enzyme are realized, the catalytic activity and the reaction rate of the enzyme are remarkably improved, and the efficiency of the whole biological catalysis process is further improved; the thermal stability, pH stability and the like of the enzyme are enhanced by a site-directed mutagenesis technology, so that the enzyme can maintain catalytic activity under wider conditions, the amino acid sequence of the enzyme is optimized, the enzyme can better adapt to specific substrates or reaction conditions, and the activity of the deoxycytidine monophosphate deaminase in a dCMP deamination reaction is improved.
Owner:HANGZHOU MEIYA PHARM CO LTD

A transient transfection method for improving recombinant protein expression in CHO cells

PendingCN122445729AEucaryotic cellDeoxycytidylic Acids
The application discloses a transient transfection method for improving recombinant protein expression of CHO cells, and relates to the technical fields of eukaryotic cell gene transfection and animal cell culture. A cell suspension is obtained by mixing a CHO cell and a serum-free CHO cell basic culture medium; DNA and a transfection reagent are added into the cell suspension to mix a transfection culture, 5-azadeoxycytidine acid solution is added into the transfection culture at 0h-24h to form a transfection system and continue the transfection culture; the transfection system is added with a feeding culture medium at 1d-4d after the transfection culture to carry out suspension culture; the suspension culture is centrifuged at 7d to separate and harvest cell culture supernatant to complete recombinant protein expression. According to the application, 5-azadeoxycytidine acid is added into the transfection culture at a specific concentration, so that the expression of recombinant protein of the CHO cell is significantly improved during the transfection expression.
Owner:SUZHOU YOUYI BIOTECHNOLOGY CO LTD

Method of purification

The invention relates to high-purity thymine, a process of purification of thymine, a process for preparing high-purity deoxythymidine, pharmaceutical compositions containing high-purity deoxythymidine and deoxycytidine as well as their use as pharmaceuticals for treatment of mitochondrial depletion syndromes in a mammal.
Owner:UCB BIOPHARMA SPRL

Enzyme composition, immobilized enzyme and application

PendingCN121380013ATransferasesOn/in organic carrierChemical synthesisThymidine Phosphorylase Deficiency
The invention discloses an enzyme composition, an immobilized enzyme and application. The enzyme composition consists of uridine phosphorylase and thymine phosphorylase. The enzyme composition and the immobilized enzyme are simple to prepare, have the characteristics of high conversion efficiency, high yield and simplicity and convenience in operation when being used for synthesizing 2 '-fluoro-2'-deoxycytidine, and can effectively reduce the production cost. Meanwhile, synthetic reaction conditions of the 2 '-fluoro-2'-deoxycytidine based on the enzyme composition and the immobilized enzyme are mild, green and environment-friendly, and the environmental problem caused by chemical synthesis can be avoided.
Owner:JIANGSU OCEAN UNIV +1

Composition for treating blood cancer using 4′-thio-5-Aza-2′-deoxycytidine and uses thereof

The present invention relates to pharmaceutical compositions for treating blood cancer, which includes 4′-thio-5-aza-2′-deoxycytidine (Aza-T-dCyd), and methods of treating blood cancer using a composition for oral administration that includes Aza-T-dCyd. The present invention provides a significant blood cancer therapeutic effect without having toxicity in a blood cancer mouse model or a human even with the Aza-T-dCyd dose conventionally known to have toxicity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:SOUTHERN RESEARCH INSTITUTE +1

Composition comprising 4'-thio-5-aza-2'- deoxycytidine for alleviating, preventing or treating liver diseases

The present invention relates to a pharmaceutical composition comprising 4'-thio-5-aza-2'-deoxycytidine or a pharmaceutically acceptable salt thereof for preventing or treating liver diseases. The 4'-thio-5-aza-2'-deoxycytidine of the present invention exhibits excellent effects with respect to treatment and alleviation of liver diseases, particularly nonalcoholic fatty liver diseases and metabolic dysfunction steatohepatitis, and thus can be effectively used for alleviation and treatment of liver diseases.
Owner:KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY

SiRNA molecule of targeted human SLC25A17 gene and application of siRNA molecule

The invention discloses a siRNA molecule targeting a human SLC25A17 gene, the siRNA molecule comprises a positive-sense strand and an antisense strand, the specific sequence is as follows: the positive-sense strand: 5 '-CCUUGGAUGUGUUCAUCAUNn-3', the antisense strand: 5 '-AUGAUGAACACAUCAAGGNn-3', N in the positive-sense strand and N in the antisense strand are the same or different, and are respectively and independently cytosine C, uracil U, guanine G, adenine A, deoxycytosine dC, deoxyguanine dG, deoxyadenine dA or deoxythymine dT; n represents the number of N, and n = 0, 1 or 2. The invention further discloses application of the siRNA molecule of the targeted human SLC25A17 gene, and the siRNA molecule is applied to liver cancer treatment by efficiently inhibiting the expression level of SLC25A17.
Owner:XIAN PEIHUA UNIV

Application of 5-fluorodeoxycytidine and medicine

PendingCN120241764AAntibacterial agentsOrganic active ingredientsReplication initiator proteinPharmaceutical drug
The invention discloses application of 5-fluorodeoxycytidine and a medicine, relates to the technical field of biological medicines, and particularly provides application of 5-fluorodeoxycytidine in preparation of a medicine for resisting staphylococcus aureus. The 5-fluorodeoxycytidine can act on staphylococcus aureus to replicate an initiator protein DnaA, inhibit the initiator protein DnaA and cause DNA replication disorder of the staphylococcus aureus, so that the activity of the staphylococcus aureus is effectively inhibited, and a bactericidal effect is achieved.
Owner:SHENZHEN PEOPLES HOSPITAL

Deoxy- cytidine derivatives for use in cancer therapies

The present invention relates to a compound of Formula (I): or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof, wherein X, W1, W2, Y, Z, R1, R2 and R3 are as defined in the disclosure herein, for use in therapy, particularly for use in the treatment of cancer. The present invention also relates to methods of treating cancer comprising the administration of a compound of Formula (I) to a subject in need thereof, and to pharmaceutical compositions and kits comprising such compounds.
Owner:TETRAGON BIOSCIENCES LTD

Method for simultaneous determination of multiple nucleotides in drinking water by solid phase extraction-liquid chromatography-mass spectrometry

The application discloses a kind of solid phase extraction-liquid quality connection simultaneously detecting multiple nucleotides in drinking water in the technical field of water pollution monitoring, first using solid phase extraction enrichment target material, nitrogen blow concentration, finally using the concentration of guanosine acid, adenosine acid, cytidine acid, uridine acid, deoxyguanosine acid, deoxyadenosine acid, deoxycytidine acid and deoxythymidine acid is determined using the multiple reaction monitoring mode of liquid chromatography tandem mass spectrometry, the present application combines solid phase extraction pretreatment technology with the detection technology of liquid chromatography tandem mass spectrometry, realizes the detection of trace nucleotide under complex matrix condition, the present application can realize the simultaneous determination of multiple nucleotides by one sample injection, with the advantages of high recovery rate, short detection time, many detection types and the like.
Owner:YANGZHOU UNIV

A fluorescent probe based on rhodamine modified nucleoside and a preparation method and application thereof

The application discloses a fluorescent probe based on rhodamine modified nucleoside and a preparation method and application thereof, and a structure formula of the fluorescent probe is as follows: the fluorescent probe is a novel fluorescent probe based on rhodamine modified nucleoside, is composed of rhodamine hydrazine-short-chain alkyne-2-deoxy cytidine, and has the advantages of high fluorescence intensity, good biological compatibility, good strong acid resistance, high sensitivity and good chemical stability. 3+ The fluorescent probe can be widely applied in the fields of in vivo and in vitro Fe detection, real-time monitoring of pH dynamics, preparation of pH test paper, cell imaging, construction of lysosome-targeting functional probes, design of in vivo contrast agents, treatment and diagnosis of gastrointestinal diseases and screening of related treatment drugs, and has great practical application value.
Owner:SHENZHEN UNIV

The invention relates to 2apos; -deoxycytidine crystal, preparation method and device

The invention relates to the technical field of preparation of 2 '-deoxycytidine crystals, and provides a 2'-deoxycytidine crystal, and a preparation method and device thereof. The method comprises the following steps: S100, dissolving 2 '-deoxycytidine in acetone to prepare a raw material solution, and adding the raw material solution into a preparation device; s200, stirring is conducted, so that a Taylor vortex flow field is formed in the preparation device, water is dropwise added into the preparation device and mixed with the raw material liquid, mixed liquid is obtained, and the volume ratio of the water to the raw material liquid is 1: 3-2: 3; s300, cooling the mixed solution at a cooling rate of 5.25 DEG C / h-6. 67 DEG C / h, cooling to 0-5 DEG C, and keeping for 8-14 hours to obtain a solid-liquid mixture; and S400, filtering and drying the solid-liquid mixture to obtain a 2 '-deoxycytidine crystal. The crystallization degree of the 2 '-deoxycytidine crystal is improved, the crystal coalescence is reduced, the operation is simple, and the cost is reduced.
Owner:TIANJIN UNIV +1

Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes

The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

EB virus related B cell lymphoma diagnostic kit based on GNAS methylation detection

The invention discloses an EB virus related B cell lymphoma diagnostic kit based on GNAS methylation detection. The invention provides a new marker for diagnosis of EB virus related B cell lymphoma, provides a matched and verified special detection primer, and performs functional reverse verification of 5-aza-2 '-deoxycytidine drug intervention. According to the invention, the potential value of the marker in the aspect of curative effect prediction is defined, and a possible molecular basis is provided for implementing individualized demethylation treatment clinically.
Owner:CENT SOUTH UNIV

Pyrimidine nucleoside treatments

The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hematological disorder, liver disease, or hepatic fibrosis, comprising administering to a subject diagnosed with said telomere biology disorder a therapeutically effective amount of said compounds.
Owner:CHILDRENS MEDICAL CENT CORP

Treatment and prevention of cardiac and fibrotic disorders

The invention relates to an oligonucleotide comprising one of the sequences selected from: (i) 5'- +T C A +G T C +T G A +T A +A G +C +T -3' (formula I); or (ii) 5'- +T C +A G T +C T G +A +T A +A G C +T -3' (formula II); wherein A, T, G and C are deoxyribonucleotide building blocks, or C is 5-methyl-2'-deoxycytidine; and wherein +T, +A, +G, and +C are bridged nucleotide building blocks and / or morpholino building blocks. Also provided are oligonucleotides and compositions comprising the same for therapeutic use.
Owner:NOVO NORDISK AS

Method for increasing the bioavailability of nucleoside drugs

Provided is a method for increasing the bioavailability of nucleoside drugs in the treatment of mitochondrial depletion syndrome. In particular, the method relates to increasing the bioavailability of deoxycytidine and deoxythymidine by administering a therapeutically effective amount of deoxycytidine and deoxythymidine with food.
Owner:UCB BIOSCIENCES INC

Use of 5-fluoro-2'-deoxycytidine in the preparation of antibacterial drugs

The present invention provides the use of 5-fluoro-2'-deoxycytidine (CDP-3) in the preparation of antibacterial drugs. The present invention discovers for the first time that CDP-3 can inhibit the synthesis of bacterial phosphatidylglycerol by targeting bacterial phosphatidylglycerol phosphate synthase, and has antibacterial and broad-spectrum synergistic activities. Its MICs against Staphylococcus aureus and Streptococcus are 4 μg / mL and 8 μg / mL respectively, and the MIC 90 against methicillin-resistant Staphylococcus aureus is 8 μg / mL, and the MIC against hypervirulent Klebsiella pneumoniae is 16 μg / mL. In addition, CDP-3 can significantly enhance the antibacterial efficacy of antibiotics such as clindamycin, tilmicosin, tetracycline, florfenicol, gentamicin, chloramphenicol, rifampicin and ofloxacin against multi-drug resistant Gram-negative bacteria, and has broad-spectrum synergistic activity. Sub-inhibitory concentrations of CDP-3 can not only inhibit bacterial growth, but also reduce bacterial biofilm formation, and inhibit virulence and pathogenicity. CDP-3 not only increases the survival rate of Galleria mellonella infected with MRSA, but also shows excellent therapeutic efficacy against animal models infected with multi-drug resistant Gram-negative bacteria.
Owner:CHINA AGRI UNIV

Carbocyclic nucleoside analogs

ActiveCN113874358BOrganic chemistryAntineoplastic agentsHydrolysisCarbocyclic nucleoside
The present invention relates to novel hydrolysis-stable carbocyclic 5-aza-2-deoxycytidine and carbocyclic 5-azacytidine compounds and prodrugs thereof as hypomethylating agents.
Owner:LUDWIG MAXIMILIANS UNIV MUNCHEN